Reperfusion in STEMI. Pharmacoinvasive therapy The Krakow experience

Size: px
Start display at page:

Download "Reperfusion in STEMI. Pharmacoinvasive therapy The Krakow experience"

Transcription

1 Reperfusion in STEMI Pharmacoinvasive therapy The Krakow experience Dariusz Dudek Jacek Legutko,, Jarosław Zalewski, Krzysztof śmudka Institute of Cardiology Jagiellonian University Medical College Krakow, Poland

2 Jagiellonian University Institute of Cardiology, Krakow, Poland 2 hospitals 5 cathlabs 26 Interventional Cardiologists 4000 PCIs / year 1500 PCI in STEMI / year

3 ESC guidelines (march 2005) STEMI (within 12 hours after onset of symptoms) Patient presenting in a hospital with PCI 3 12 h Patient presenting in a hospital without PCI <3 h Immediate transfer Thrombolysis Failed Successful PCI 24h available PCI 24h not available Predischarge ischaemia Primary PCI Rescue PCI Post thrombolysis PCI Ischaemiaguided PCI

4 How to Optimize Primary PCI? Improvement of myocardial reperfusion Gp IIb/IIIa proven efficacy (class IIaA) mechanical protection thrombectomy, distal and proximal protection (class IIb C). No routine use, but: Better ST resolution, MPG no MACEs improvement, no EF? Reduction of TVR during long term follow up DES

5 Acute MI < 12 hrs in the region of 3.2 mln inhibitants Ia Ib transfer < 90min (Ib) transfer < 30min (Ia) TELE EKG abciximab Cathlab Thrombectomy and PCI PCI and abciximab PCI

6 Impact of Early Abciximab Administration before Primary Percutaneous Coronary Interventions in Anterior Myocardial Infarction on Reperfusion and Left Ventricular Function (n=59 pts) BASELINE ANGIOGRAPHY 80% 60% 48% 40% 20% p= % Early Abciximab Late Abciximab STSEGMENT RESOLUTION 60min AFTER PCI 100% 80% 60% 40% 20% 84% p= ,7% 52% p= ,3% 0% TIMI 2+3 0% STR>50% STR>70% AUC 5938+/ U/l x h CKMB AUC during 48h AUC 8324+/ U/l x h p= CARDIAC MAGNETIC RESONANCE AT 1 YEAR p=0.02 LEFT VENTRICULAR ESVI END SYSTOLIC VOLUME INDEX T.Rakowski, D. Dudek et al., AJC 2005 (TCT oral presentation)

7 EUROTRANSFER Registry European Registry on Patients with STElevation MI Transferred for Mechanical Reperfusion (PCI) with a Special Focus on Upstream Use of Abciximab. Principal Investigator Dariusz Dudek MD, PhD Director, Cardiac Catheterization Laboratories University Hospital, Krakow, Poland

8 EUROTRANSFER Registry currently participating centres Helsinki FINLAND Linkoping SWEDEN Przemysl POLAND Krakow POLAND Zabrze POLAND Rostock GERMANY Villingen Schwenningen GER Leeds ENGLAND Santiago de Compostela SPAIN Coruna SPAIN Treviso ITALY Reggio Emilia ITALY Mantova ITALY Arezzo ITALY Ljubljana SLOVENIA Nowy Sacz POLAND Tarnow POLAND Massa ITALY Brussels BELGIUM Lund SWEDEN Bad Oeynhausen GERMANY

9 PolishItalianHungarian Randomized ThrombEctomy Trial PIHRATE Trial PI: Dariusz Dudek

10 PIHRATE Trial n=200 pts STEMI <6hr ST elevation >3 mm in one lead TIMI 0 or 1 TIMI, ctfc, MBG RANDOMIZATION TIMI 0 or 1 POBA STENTING Grup I (n=100) THROMBECTOMY TIMI, ctfc, MBG TIMI 2 or 3 DIRECT STENTING TIMI, ctfc, MBG Grup II (n=100) PREDILATATION TIMI, ctfc, MBG STENT IMPLANTATION TIMI, ctfc, MBG ST SEGMENT RESOLUTION 60 MINUTES AFTER PCI CK/CKMB LEAK: every 6 hours for 24 hours ECHO: EF, ESV, EDV, WMSI predischarge and 6 month follow up CMR in the subgroup of patients EDV, ESV, mass and ejection fraction, delayedcontrastenhancement 6 months follow up MACE: 30 day and 6 month follow up

11 Delay >60 minutes 6090 (120) minutes >90 (120) minutes ASA / 600mg clopidogrel / UFH TIME DELAY TRANSFER WITH LYTIC / GPIIbIIIa inhibitor / COMBO THERAPY TRANSFER WITHOUT LYTIC / GPIIbIIIa inhibitor / COMBO THERAPY

12 Why to transfer patients after lytic therapy, when delay to PCI > 120 min? 1. No recommendation in guidelines to transfer patients without lytic with delay >120 min 2. Conservative treatment in hospitals without cath labs provides inferior results to PCI 3. When rescue PCI is necessary patient will be in high volume center (why to keep high risk patients 6090 minutes longer in local hospitals for reperfusion assessment in ecg?) 4. Post lytic PCI within 24 hours is recommended in guidelines

13 p. miechowski 51,5 tys. p. olkuski 114,7 tys. mortality 3.5% Kraków + p. krakowski 998,8 tys. p. proszowicki 43,6 tys. p. dąbrowski 58,6 tys year p. oświęcimski 153,1 tys. p. chrzanowski 128,7 tys. p. wadowicki 153,4 tys. pierwotna PCI p. wielicki 102,5 tys. p. myślenicki 114,9 tys. p. suski p. limanowski 81,5 tys. 120,2 tys. p. nowotarski 179,9 tys. p. bocheński 99,7 tys. Tarnów + p. brzeski p. tarnowski 89,7 tys. 310,5 tys. Nowy Sącz + p. nowosądecki 279,4 tys. p. gorlicki 106,4 tys. 23 hospitals referring STEMI pts to Krakow Center ½ tpa +abciximab and transfer FACILITATED PCI p. tatrzański 65,3 tys.

14 2 years June 2001 June 2003 STEMI n=2362 (age <75 years) PRIMARY PCI vs FACILITATED PCI 30day MACE 8% 6% 4% 3,4% 3,0% NS 4,2% 3,9% 5,0% 4,8% 2% 0,8% 0,9% 0,8% 0,9% 0% Death re MI re PCI death + re MI All MAC E PRIMARY FACILITATED D. Dudek et al., AJC 2003 D. Dudek et al., AHA 2005, featured research

15 Primary PCI vs. ReducedDose Facilitated PCI Death Reinfarction Revascularization Bleeding P Value Facilitated Lytic Alone P Value Facilitated Lytic Alone P Value Facilitated Lytic Alone P Value Facilitated Lytic Alone Authors Titles Ross et al. PACT 3.3% 3.6% % 3% % 7.3% % 12.9% 0.84 Dudek et al. 3.5% 1.0% 1.5% 3.0% Kastrati et al. BRAVE 1.6% 1.6% NS 0% 0.8% NS 1.6% 5.6% 0.16 Maioli et al. 6.1% 6.3% % 0% % 6.2% ADVANCE MI Inv. ADVANCE MI 0% 6.8% % 1.4% % 23% 0.05 Borden and Faxon, J Am Coll Cardiol, 2006;48:1120 8

16 ST,, high risk, lytic lyticeligible, < h UFH UFH U/kg U/kg (max (max 3000); 3000); 7 U/kg/h U/kg/h Reteplase 2 x 5 U bolus bolus (30 ) (30 ) Abciximab mg/kg mg/kg bolus; bolus; µg/kg/min µg/kg/min x h (maximum 10 µg/min) (maximum 10 µg/min) IMMEDIATE PCI Immediate Transfer Transfer to to Cath CathLab for for PCI; PCI; after after PCI PCI pat. pat. remains remains in in the the hospital hospital where where PCI PCI was was performed or or is is transferred back back to to referring hospital hospital MEDICAL TREATMENT + RESCUE CCU CCU Admission; Transfer Transfer for for PCI PCI only only if if persistent ST ST elevation at at min min (>50% (>50% basal basal ECG), ECG), chest chest pain pain or or hemodynamic compromise Primary Endpoint: Death, Reinfarction,, Refractory Ischemia at at Days Days Di Mario, Bolognese, Maillard, Dudek et al Am Heart J, 2004

17 2 new centers with 24h/7days service for 0.5 mln population each p. oświęcimski 153,1 tys. p. chrzanowski 128,7 tys. p. wadowicki 153,4 tys. p. olkuski 114,7 tys. p. miechowski 51,5 tys. p. proszowicki Kraków + 43,6 tys. p. krakowski 998,8 tys ,2 tys. SMALL NETWORK for 0.5 mln inhabitatns p. bocheński 99,7 tys. p. wielicki 102,5 tys. p. brzeski 89,7 tys. app. 350 STEMI PCI/ year app. 350 NSTEMI/UA PCI/ year 45 operators p. dąbrowski 58,6 tys. Tarnów + p. tarnowski 310,5 tys. 458,8 tys year FACILITATED PCI CARESS study p. suski 81,5 tys. p. nowotarski 179,9 tys. p. myślenicki 114,9 tys. p. tatrzański 65,3 tys. p. limanowski 120,2 tys. 506 tys. Nowy Sącz + p. nowosądecki 279,4 tys. p. gorlicki 106,4 tys. SMALL NETWORK for 0.5 mln inhabitatns app. 350 STEMI PCI/ year app. 350 NSTEMI/UA PCI/ year 45 operators

18 Primary PCI Clinical usefulness of different thrombectomy devices during primary PCI needs further clinical trials DES for Primary PCI need large clinical studies with long term outcome

19 Gp IIb/IIIa inhibitors and Primary PCI 1. In STEMI patients, pharmacologic pretreatment prior to PCI improves initial TIMI3 flow 2. It is reasonable to start GPIIb/IIIa as early as possible prior to primary angioplasty 3. Early IIb/IIIa administration could be more beneficial for higher risk AMI, early presenters and when time to PCI is longer (app. 60 minutes door to balloon time)

20 Fibrynolysis & PCI 1. Facilitated PCI with full dose lytic is not recommended (early routine PCI<12 hrs and immediate after lysis) 2. Pharmaco invasive therapy is permitted and recommended by ESC guidelines (PCI within 24 hrs after lysis). 3. Pharmaco invasive therapy could be recommended for STEMI < 23 hrs onset when long delay > 120 minut expected 4. High risk pts after lytic should be tranfered to PCI centers for clinical/angio evaluation (rescue PCI; PCI 24 hrs)

PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators

PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators Polish-Italian-Hungarian Randomized ThrombEctomy Trial PIHRATE Trial On behalf PIHRATE investigators Dariusz Dudek MD, PhD Institute of Cardiology, Krakow, Poland Impact of distal embolization Distal embolization

More information

Networking for optimal treatment of STEMI and NSTEMI. European Stent for life Project

Networking for optimal treatment of STEMI and NSTEMI. European Stent for life Project Networking for optimal treatment of STEMI and NSTEMI European Stent for life Project Dariusz Dudek on behalf of Department of Interventional Cardiology, Institute of Cardiology, Krakow, Poland The European

More information

The FINESSE Trial. (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) Stephen Ellis, MD For the FINESSE Investigators

The FINESSE Trial. (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) Stephen Ellis, MD For the FINESSE Investigators The FINESSE Trial (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) Stephen Ellis, MD For the FINESSE Investigators ESC Vienne 2007 Rational for FINESSE Time is muscle: early reperfusion

More information

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO REFERRAL HOSPITAL The Importance of Door In Door Out Time DIDO Time to Treatment is critical for STEMI patients For patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary

More information

Il punto sulla terapia antitrombotica nelle sindromi coronariche acute

Il punto sulla terapia antitrombotica nelle sindromi coronariche acute Santa Margherita Ligure TIGULLIO CARDIOLOGIA 2012 16-17 Febbrajo 2012 Il trattamento dell infarto miocardico acuto ad ST spraslivellato: dal territorio al laboratorio di emodinamica Il punto sulla terapia

More information

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

BRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the

BRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI Thirty-Day and One-Year Outcomes of the BRIGHT Trial Yaling Han, MD, FACC On behalf of the BRIGHT investigators

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

Implementing a Prehospital 12-Lead Program

Implementing a Prehospital 12-Lead Program Implementing a Prehospital 12-Lead Program Corey M. Slovis, M.D. Professor and Chairman Department of Emergency Medicine Vanderbilt University Medical Center Medical Director, Metro Nashville Fire Department

More information

ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline

ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline David Zhao, MD, FACC, FSCAI Professor of Medicine and Cardiac Surgery Harry and Shelley Page Professor in Interventional Cardiology

More information

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015 Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?

More information

έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν

έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν ΝΠθ ζζάθδκνσθϋ λδκν έΰκ μνεδν ιωθκ κεκη δεάμνι λδεάμ έΰζβν έκ,νσϊίί κν1γν λδζέκνβί1γ Α Α φ ; έζ δκμννένσθόμ ηί δεόμνκλ δκζόΰκμ, θν δ γθ άμνγνκλ /εάμ ΚζδθδεάμΝ λωεζδθδεάμν ένivus Scientific Director, Mediolanum

More information

DATE: 29 August 2012 CONTEXT AND POLICY ISSUES

DATE: 29 August 2012 CONTEXT AND POLICY ISSUES TITLE: Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence DATE: 29 August 2012 CONTEXT AND POLICY

More information

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management

More information

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen

More information

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example Ulf Stenestrand, MD, PhD Department of Cardiology University Hospital Linköping Chairman RIKS-HIA Register

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent

More information

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Stent for Life Initiative How can we improve system delay and patients delay in STEMI Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration

More information

ESC PCI Guidelines: / Sigmund Silber et al. 1

ESC PCI Guidelines: / Sigmund Silber et al. 1 For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction

More information

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Acute Coronary Syndromes: oral antithrombotic therapy Focus on

More information

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore

More information

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION

More information

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize

More information

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015 Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet

More information

Utilizing the Cath Lab for Cardiac Arrest

Utilizing the Cath Lab for Cardiac Arrest Utilizing the Cath Lab for Cardiac Arrest Khaled M. Ziada, MD Director, Cardiovascular Catheterization Laboratories Gill Heart Institute, University of Kentucky UK/AHA Strive to Revive Symposium May 2013

More information

Antonio Colombo MD on behalf of the SECURITY Investigators

Antonio Colombo MD on behalf of the SECURITY Investigators Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY

More information

Management of Acute Coronary Syndrome / NSTEMI

Management of Acute Coronary Syndrome / NSTEMI CLINICAL GUIDELINE Management of Acute Coronary Syndrome / NSTEMI For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: All clinical areas Medical and

More information

Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC

Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC NAAMA 37 th National Medical Convention September 5 th, 2015 Atherosclerosis Coronary Heart

More information

Translating Science to Health Care: the Use of Predictive Models in Decision Making

Translating Science to Health Care: the Use of Predictive Models in Decision Making Translating Science to Health Care: the Use of Predictive Models in Decision Making John Griffith, Ph.D., Associate Dean for Research Bouvé College of Health Sciences Northeastern University Topics Clinical

More information

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos

More information

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,

More information

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France

More information

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf

More information

Canadian Journal of Cardiology 27 (2011) 529 533. Editorial

Canadian Journal of Cardiology 27 (2011) 529 533. Editorial Canadian Journal of Cardiology 27 (2011) 529 533 Editorial From Primary to Secondary Percutaneous Coronary Intervention: The Emerging Concept of Early Mechanical Reperfusion With Delayed Facilitated Stenting

More information

Trial Design. From the a Southlake Regional Health Centre, Newmarket, Ontario, Canada, b University of Toronto, Toronto, Ontario, Canada,

Trial Design. From the a Southlake Regional Health Centre, Newmarket, Ontario, Canada, b University of Toronto, Toronto, Ontario, Canada, Trial Design Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) Warren J. Cantor, MD, a,b David

More information

6.3. Management 6.3.1. Routine Measures

6.3. Management 6.3.1. Routine Measures ACC/AHA 2004 Practice Guidelines for STEMI 6.3. Management 6.3.1. Routine Measures 6.3.1.1. Oxygen Supplemental oxygen should be administered to patients with arterial oxygen desaturation (SaO2 less than

More information

California Health and Safety Code, Section 1256.01

California Health and Safety Code, Section 1256.01 California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program

More information

The Cardiac Society of Australia and New Zealand

The Cardiac Society of Australia and New Zealand The Cardiac Society of Australia and New Zealand Guidelines on Support Facilities for Coronary Angiography and Percutaneous Coronary Intervention (PCI) including Guidelines on the Performance of Procedures

More information

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor

More information

Como mejorar el manejo médico de los diabéticos con SCA

Como mejorar el manejo médico de los diabéticos con SCA DIABETES Y ENFERMEDAD CORONARIA EN 2011 Como mejorar el manejo médico de los diabéticos con SCA Antonio Fernández-Ortiz Jueves, 20 Octubre 2011 INSTITUTO CARDIOVASCULAR Conflicto de interés: Antonio Fernández-Ortiz

More information

L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001

L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001 L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and

More information

La facilitazione alla PCI con statine

La facilitazione alla PCI con statine La facilitazione alla PCI con statine Bertinoro, 16 aprile 2010 Aldo Miola, M.D., Ph.D. Medical Manager Primary Care Pfizer Italy 1 Are statins beneficial in patients undergoing PCI? 2 3 Statin therapy

More information

Disclosures. The FAST-MI registry is a registry of the French Society of Cardiology, supported by unrestricted grants from:

Disclosures. The FAST-MI registry is a registry of the French Society of Cardiology, supported by unrestricted grants from: Impact on early complications of non-compliance with guidelines-recommended timelines for reperfusion therapy in STEMI patients. The FAST-MI 2010 registry E. Puymirat 1, L. Lorgis 2, P. Coste 3, S. Charpentier

More information

Aktuelle Literatur aus der Notfallmedizin

Aktuelle Literatur aus der Notfallmedizin 05.02.2014 Aktuelle Literatur aus der Notfallmedizin prä- und innerklinisch Aktuelle Publikationen aus 2012 / 2013 PubMed hits zu emergency medicine 12,599 Abstract OBJECTIVES: Current American Heart

More information

Improving PCI Benchmark times in a Non-PCI World

Improving PCI Benchmark times in a Non-PCI World Improving PCI Benchmark times in a Non-PCI World May 2011 St David s Georgetown Hospital, Georgetown Texas Margaret Connors BSN, RN, CEN Kirk Sinclair BSN, RN, CEN National Processes/ Mission LifeLine

More information

EMR Tutorial Acute Coronary Syndrome

EMR Tutorial Acute Coronary Syndrome EMR Tutorial Acute Coronary Syndrome How to find the Acute Coronary Syndrome AAA Home Page 1 of 26 Master Tool Bar Icon When the Template button is clicked you will be presented with the preference list.

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

Mission: Lifeline Recommendations for Criteria for STEMI Systems of Care

Mission: Lifeline Recommendations for Criteria for STEMI Systems of Care Mission: Lifeline Recommendations for Criteria for STEMI Systems of Care The Mission: Lifeline Certification Program will acknowledge STEMI Systems, EMS, Non-PCI/STEMI Referral Centers and PCI/STEMI Receiving

More information

Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH

Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH PAUL N. CASALE, M.D., F.A.C.C. Chief, Division of Cardiology and Medical Director of Cardiology, Lancaster General Hospital

More information

OCT STEMI: OCT guidance during stent implantation

OCT STEMI: OCT guidance during stent implantation OCT STEMI: OCT guidance during stent implantation in primary PCI. A Randomized Multicenter study with 9-month optical coherence tomography follow-up Červinka P 1,2, Kala P 3, Jakl M 2,4, Kaňovský J 3,

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

STEMI Care in WV Mission: Lifeline -AHA initiative. Christopher B. Granger, MD, FACC Mayme Lou Roettig, RN, MSN

STEMI Care in WV Mission: Lifeline -AHA initiative. Christopher B. Granger, MD, FACC Mayme Lou Roettig, RN, MSN STEMI Care in WV Mission: Lifeline -AHA initiative Christopher B. Granger, MD, FACC Mayme Lou Roettig, RN, MSN Christopher B. Granger, MD, F.A.C.C Director of Cardiac Care Unit Duke University Medical

More information

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:

More information

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics Yen Tibayan, M.D. Division of Cardiovascular Medicine Case Presentation 69 y.o. woman calls 911 with the complaint of

More information

National Medicines Information Centre

National Medicines Information Centre National Medicines Information Centre VOLUME 11 NUMBER 4 2005 ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie For personal use only. Not to be reproduced without

More information

How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne

How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne What do the guidelines say? What happens with warfarin

More information

Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands

Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting

More information

Optimal Duration of Dual Antiplatelet Therapy

Optimal Duration of Dual Antiplatelet Therapy Optimal Duration of Dual Antiplatelet Therapy Luis A Guzman, MD, FACC, FSCAI Associate Professor of Medicine Director, Cardiac and Vascular Cath Lab University of Florida College of Medicine - Jacksonville

More information

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die

More information

Mission: Lifeline EMS Recognition Guide

Mission: Lifeline EMS Recognition Guide Mission: Lifeline EMS Recognition Guide This Mission: Lifeline EMS Recognition Guide was developed to provide information about Mission: Lifeline EMS Recognition processes and criteria. If you have any

More information

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D. Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University

More information

Māori Pathways to and Through Health Care for STEMIs in New Zealand. Summer Studentship Research by Ellie Tuzzolino- Smith

Māori Pathways to and Through Health Care for STEMIs in New Zealand. Summer Studentship Research by Ellie Tuzzolino- Smith Māori Pathways to and Through Health Care for STEMIs in New Zealand Summer Studentship Research by Ellie Tuzzolino- Smith Terminology & Current Practice STEMI: S-T elevation Myocardial Infarction. Determined

More information

URN: Family name: Given name(s): Address:

URN: Family name: Given name(s): Address: State of Queensland (Queensland Health) 2015 Licensed under: http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en Contact: Clinical_Pathways_Program@health.qld.gov.au Facility:... Clinical pathways

More information

What s New in Stroke?

What s New in Stroke? 5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario

More information

Is There A LIfe for DES after discontinuation of Clopidogrel

Is There A LIfe for DES after discontinuation of Clopidogrel Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:

More information

MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE. Peter Wenaweser Universitätsklinik für Kardiologie

MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE. Peter Wenaweser Universitätsklinik für Kardiologie MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE Peter Wenaweser Universitätsklinik für Kardiologie Scientific Advances & Cardiovascular Mortality 1950 to 2010 Nabel EM and Braunwald

More information

Non-invasive functional testing in 2014

Non-invasive functional testing in 2014 Non-invasive functional testing in 2014 Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Disclosures: Research grants: Edwards and Siemens Non-invasive functional testing in 2014

More information

S Hutton, A Inglis, C McKiernan, S Hearns, P Campbell, M Lindsay

S Hutton, A Inglis, C McKiernan, S Hearns, P Campbell, M Lindsay Emergency Medical Retrieval Service (EMRS) www.emrs.scot.nhs.uk Standard Operating Procedure Public Distribution Title Acute Coronary Syndrome Version 4 Related Documents Author Alan Exton Reviewer S Hutton,

More information

ACTION Registry GWTG Version 2.4

ACTION Registry GWTG Version 2.4 ACTION Registry GWTG Version 2.4 Dr. Joanne Foody Kim Hustler The following relationships exist: Dr. Foody:Janssen, Sanofi, Genzyme, Aegerion, Amarin, BristolMeyersSquibb, Abbott, Gilead, ACC, Pfizer,

More information

Scelte Antitrombotiche nelle SCA delle UTIC Italiane: Nuovi Dati dal Registro EYESHOT

Scelte Antitrombotiche nelle SCA delle UTIC Italiane: Nuovi Dati dal Registro EYESHOT CARDIOLUCCA 2014 HEART CELEBRATION Lucca, palazzo Ducale Sala Ademollo 27-29 Novembre 2014 Scelte Antitrombotiche nelle SCA delle UTIC Italiane: Nuovi Dati dal Registro EYESHOT Leonardo De Luca, MD, PhD,

More information

B etween 30% and 50% of patients with acute myocardial

B etween 30% and 50% of patients with acute myocardial 330 ORIGINAL ARTICLE Rescue percutaneous coronary intervention for failed thrombolysis: results from a district general hospital K P Balachandran, J Miller, ACHPell, B D Vallance, K G Oldroyd... Postgrad

More information

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan

More information

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of

More information

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University

More information

ST Segment Elevation Nothing is ever as hard (or easy) as it looks

ST Segment Elevation Nothing is ever as hard (or easy) as it looks ST Segment Elevation Nothing is ever as hard (or easy) as it looks Cameron Guild, MD Division of Cardiology University of Mississippi Medical Center February 17, 2012 Objectives 1. Describe the electrical

More information

HA Territory-wide PCI Audit 2003-05

HA Territory-wide PCI Audit 2003-05 HA Territory-wide PCI Audit 23-5 5 PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 26 Percutaneous Coronary Intervention Background HA AP target 2/3, coordinated by PCI Working

More information

Redefining the NSTEACS pathway in London

Redefining the NSTEACS pathway in London Redefining the NSTEACS pathway in London Sotiris Antoniou Consultant Pharmacist, Cardiovascular Medicine, Barts and The London NHS Trust and Project Lead, North East London Cardiovascular and Stroke Network

More information

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications

More information

The Bioresorbable Vascular Stent Dr Albert Ko

The Bioresorbable Vascular Stent Dr Albert Ko The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of

More information

1 / 174. Xavier Bosch. Authors. Contact person. Dates. Review No. What's new

1 / 174. Xavier Bosch. Authors. Contact person. Dates. Review No. What's new Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-st segment elevation acute coronary syndromes (9819) Review information Authors

More information

Guidelines for Percutaneous Coronary Interventions

Guidelines for Percutaneous Coronary Interventions Publish-Ahead-of-Print published March 29, 2005 European Heart Journal doi:10.1093/eurheartj/ehi138 ESC Guidelines Guidelines for Percutaneous Coronary Interventions The Task Force for Percutaneous Coronary

More information

How do you decide on rate versus rhythm control?

How do you decide on rate versus rhythm control? Heart Rhythm Congress 2014 How do you decide on rate versus rhythm control? Dr Ed Duncan Consultant Cardiologist & Electrophysiologist Define Rhythm Control DC Cardioversion Pharmacological AFFIRM study

More information

Mission: Lifeline North Texas STEMI Workshop. The Model STEMI Referring Center (non-pci capable) Trisha Wren, RN, BSN

Mission: Lifeline North Texas STEMI Workshop. The Model STEMI Referring Center (non-pci capable) Trisha Wren, RN, BSN STEMI Workshop The Model STEMI Referring Center (non-pci capable) Trisha Wren, RN, BSN Faculty Disclosure Information Trisha Wren, RN, BSN The Model STEMI Referring Center (non PCI capable) FINANCIAL DISCLOSURE:

More information

Triple thérapie anti-thrombotique chez le coronarien. Y Cottin Dijon

Triple thérapie anti-thrombotique chez le coronarien. Y Cottin Dijon Triple thérapie anti-thrombotique chez le coronarien Y Cottin Dijon «Dans la vie, rien n est à craindre, tout est à comprendre» Marie Curie Epidémiologie Aspirine/Clopidogrel/Ticagrelor/Prasugrel Durée?

More information

Gregg W. Stone, MD. Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation

Gregg W. Stone, MD. Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation INFUSE-AMI A 2x2 Factorial, Multicenter, Prospective, Randomized Evaluation of Intracoronary Abciximab and Aspiration Thrombectomy in Patients Undergoing Primary PCI for Anterior STEMI Gregg W. Stone,

More information

Clinical Results of Unprotected Left Main Coronary Stenting

Clinical Results of Unprotected Left Main Coronary Stenting Original Articles IMAJ VOL 11 MARCH 2009 Clinical Results of Unprotected Left Main Coronary Stenting Itsik Ben-Dor MD, Hana Vaknin-Assa MD, Eli Lev MD, David Brosh MD, Shmuel Fuchs MD, Abid Assali MD and

More information

Endoscopy & ACS. 8/1/2014 Dr. Whang

Endoscopy & ACS. 8/1/2014 Dr. Whang Endoscopy & ACS 8/1/2014 Dr. Whang Outline I. Antiplatelets II. Coronary Artery Disease in U.S. III. GI Bleeding in ACS IV. ACC/AHA guidelines: Dual Antiplatelet Therapy in CAD V. PPI and Plavix Controversy

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

European Resuscitation Council Guidelines for Resuscitation 2005 Section 5. Initial management of acute coronary syndromes

European Resuscitation Council Guidelines for Resuscitation 2005 Section 5. Initial management of acute coronary syndromes Resuscitation (2005) 67S1, S87 S96 European Resuscitation Council Guidelines for Resuscitation 2005 Section 5. Initial management of acute coronary syndromes Hans-Richard Arntz, Leo Bossaert, Gerasimos

More information

Description of problem Description of proposed amendment Justification for amendment ERG response

Description of problem Description of proposed amendment Justification for amendment ERG response KEY INACCURACIES Issue 1 Distinguishing between groups of STEMI patients Key issue throughout the report The ERG distinguishes between groups of STEMI patients defining four patient groups: STEMI without

More information

HAAD JAWDA Quality KPI; waiting times. December 2015

HAAD JAWDA Quality KPI; waiting times. December 2015 HAAD JAWDA Quality KPI; waiting times December 2015 Page 1 of 13 Type: Waiting Time Indicator Indicator Number: WT001 Primary Care Appointment- Outpatient Setting Time to see a HAAD licensed family physician

More information

SIGN 93 Acute coronary syndromes. A national clinical guideline Updated February 2013

SIGN 93 Acute coronary syndromes. A national clinical guideline Updated February 2013 Help us to improve SIGN guidelines - click here to complete our survey SIGN 93 Acute coronary syndromes A national clinical guideline Updated February 2013 Evidence KEY TO EVIDENCE STATEMENTS AND GRADES

More information

Elderly Patients with renal insufficiency: Which anti-platelet/ Anti thrombin/minimizing Major bleeds

Elderly Patients with renal insufficiency: Which anti-platelet/ Anti thrombin/minimizing Major bleeds Elderly Patients with renal insufficiency: Which anti-platelet/ Anti thrombin/minimizing Major bleeds Blair J O Neill MD FRCPC FACC Text Professor of Medicine, University of Alberta Clinical Co-Director

More information

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br. The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies Christoph Hehrlein, University Clinic Freiburg i.br. Germany Disclosure Statement of Financial Interest Within the past 12 months,

More information

Acute Coronary Syndromes Education for Healthcare Providers. Hani Kozman, MD Cardiology Division SUNY Upstate Medical University

Acute Coronary Syndromes Education for Healthcare Providers. Hani Kozman, MD Cardiology Division SUNY Upstate Medical University Acute Coronary Syndromes Education for Healthcare Providers Hani Kozman, MD Cardiology Division SUNY Upstate Medical University NSTEMI 2 Types ACS: Chest pain related to a progressively enlarging intracoronary

More information

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:

More information